Journal of Radioanalytical and Nuclear Chemistry

, Volume 303, Issue 1, pp 979–983 | Cite as

Astatine-211 labeling: a study towards automatic production of astatinated antibodies

  • Emma Aneheim
  • Holger Jensen
  • Per Albertsson
  • Sture Lindegren


Targeted alpha therapy is especially interesting for therapy of microscopic cancer tumors due to short path length and high linear energy transfer of the alpha particles. One of the most promising nuclides for targeted alpha therapy is 211At. To facilitate larger clinical studies using 211At, the current manual synthesis of radiolabeled antibodies would benefit from being transferred into an automated method. In this work, successful modifications of the manual synthesis have been performed in order to adapt it to automation. The automatic synthesis has also been tested using the modified synthesis method.


211At Labeling Immunoconjugates Antibodies Radiopharmaceutical module 



The Inga Britt and Arne Lundbergs Research Foundation, The Swedish Cancer Society and the King Gustaf V Jubilee Clinic Research Foundation are acknowledged for the funding of this work.


  1. 1.
    Elgqvist J, Frost S, Pouget J-P, Albertsson P (2014) Front Oncol 3(324):1–9Google Scholar
  2. 2.
    Choppin G, Liljenzin J-O, Rydberg J (2002) Radiochemistry and Nuclear Chemistry. Butterworth-Heinemann, WoburnnGoogle Scholar
  3. 3.
    Kim Y-S, Brechbiel MW (2012) Tumor Biol 33:573–590CrossRefGoogle Scholar
  4. 4.
    Rajpar S, Fizazi K (2013) Cancer J 19:66–70CrossRefGoogle Scholar
  5. 5.
    Huclier-Markai S, Alliot C, Varmenot N, Cutler CS, Barbet J (2013) Curr Top Med Chem 23:2642–2654CrossRefGoogle Scholar
  6. 6.
    Kassis AI, Harris CR, Adelstein SJ (1986) Radiat Res 105:27–36CrossRefGoogle Scholar
  7. 7.
    Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L (2005) J Nucl Med 46:1907–1915Google Scholar
  8. 8.
    Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L (2006) J Nucl Med 47:1342–1350Google Scholar
  9. 9.
    Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, Jacobsson L (2009) Cancer Biother Radiopharm 24:649–658CrossRefGoogle Scholar
  10. 10.
    Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J (2009) J Nucl Med 50:1153–1160CrossRefGoogle Scholar
  11. 11.
    Cederkrantz E (2014) Doctoral thesis available at: Accessed 27 June 2014
  12. 12.
    Zalutsky MR, Zhao X-G, Alston KL, Bigner D (2001) J Nucl Med 42:1508–1515Google Scholar
  13. 13.
    Lindegren S, Frost S, Bäck T, Haglund E, Elgqvist J, Jensen H (2008) J Nucl Med 49:1537–1545CrossRefGoogle Scholar
  14. 14.
    Lambert JL, Ramasamy J, Paukstelis JV (1975) Anal Chem 47:916–918CrossRefGoogle Scholar
  15. 15.
    Li CH, White CF (1943) J Am Chem Soc 65:335–339CrossRefGoogle Scholar
  16. 16.
    Beebe TR, Adkins M, Kwok P, Roehm R (1972) J Org Chem 37:4220–4222CrossRefGoogle Scholar
  17. 17.
    Horacek J, Skladal P (1998) Chem Pap 52:294–295Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2014

Authors and Affiliations

  • Emma Aneheim
    • 1
  • Holger Jensen
    • 2
  • Per Albertsson
    • 1
  • Sture Lindegren
    • 1
  1. 1.Targeted Alpha Therapy Group, Department of Radiation PhysicsSahlgrenska Academy at Gothenburg UniversityGothenburgSweden
  2. 2.PET and Cyclotron UnitCopenhagen University HospitalCopenhagenDenmark

Personalised recommendations